|
[Related PubMed/MEDLINE]
Total Number of Papers: 113
|
|
|
|
|
[Display Entries]
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: CDAI |
| Long Form |
: CD activity index |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. |
CD, CDEIS, CRP, FC |
| 2 |
2020 |
Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: A Systematic Review and Pooled Meta-analysis. |
CD, OR, TNF |
| 3 |
2020 |
Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses. |
CD, CI, CR, OR |
| 4 |
2020 |
Efficacies and Related Issues of Ustekinumab in Japanese Patients with Crohn's Disease: A Preliminary Study. |
CD, LOR, UST |
| 5 |
2020 |
Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial. |
AEs, CD, SD |
| 6 |
2020 |
Fecal MicroRNAs Show Promise as Noninvasive Crohn's Disease Biomarkers. |
CD, CDEIS, miRNAs |
| 7 |
2020 |
Increased Faecalibacterium abundance is associated with clinical improvement in patients receiving rifaximin treatment. |
CD, DD, GSS, IBS, IBS-SSS, UC |
| 8 |
2020 |
Platelets can reflect the severity of Crohn's disease without the effect of anemia. |
CD, CRP, IBD, IDA, PLT, ROC, UC |
| 9 |
2020 |
Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial. |
CALM, CD, CM, ICER, QALYs, TC |
| 10 |
2019 |
Characteristics of mucosa-associated gut microbiota during treatment in Crohn's disease. |
CD, HC, MDI |
| 11 |
2019 |
Elevated Levels of Alveolar Nitric Oxide May Indicate Presence of Small Airway Inflammation in Patients with Inflammatory Bowel Disease. |
CANO, CD, eNO, FeNO, IBD, UC |
| 12 |
2019 |
Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease. |
CD, CI, SES-CD, TNF |
| 13 |
2019 |
Treatment sequence network meta-analysis in Crohn's disease: a methodological case study. |
CD, NMA, RCTs |
| 14 |
2019 |
Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease. |
CD, SES-CD |
| 15 |
2018 |
A multicenter, prospective, observational study of the long-term outcomes of Crohn's disease patients under routine care management in Greece. |
CD, TNF |
| 16 |
2018 |
Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy. |
CD, CR-50, CRP, EOW |
| 17 |
2018 |
Prediction of clinical outcomes in Crohn's disease by using confocal laser endomicroscopy: results from a prospective multicenter study. |
CD, CDEIS, CLE, CRP, RR |
| 18 |
2018 |
Serum amyloid A level correlated with endoscopic findings in patients with Crohn's disease-Possible biomarker for evaluating mucosal healing. |
CD, MH, ROC, SAA, SES-CD |
| 19 |
2018 |
The potential role of FDG PET-CT in the characterization of the activity of Crohn's disease, staging follow-up and prognosis estimation: a pilot study. |
CD, SES-CD |
| 20 |
2018 |
The utility of food antigen test in the diagnosis of Crohn's disease and remission maintenance after exclusive enteral nutrition. |
CD, CRP, EEN, ESR |
| 21 |
2018 |
Utility of video capsule endoscopy for longitudinal monitoringof Crohn's disease activity in the small bowel:aprospective study. |
CD, CE, CECDEIS, HBI, PGA, SES-CD |
| 22 |
2017 |
CT Enterography for Surveillance of Anastomotic Recurrence within 12 Months of Bowel Resection in Patients with Crohn's Disease: An Observational Study Using an 8-Year Registry. |
CD, CTE |
| 23 |
2017 |
Effect of Electro-Acupuncture and Moxibustion on Brain Connectivity in Patients with Crohn's Disease: A Resting-State fMRI Study. |
CD, DMN, IBDQ, MCC, rsFC |
| 24 |
2017 |
Is Oxidative Stress Associated with Activation and Pathogenesis of Inflammatory Bowel Disease? |
CD, EAI, IBD, OSI, TAS, TOS, UC |
| 25 |
2017 |
Oral mucosa lesions in patients with active Crohn’s disease - a prospective study. |
CD |
| 26 |
2017 |
Possible undertreatment of women with Crohn disease in Poland. A subgroup analysis from a prospective multicenter study of patients on anti-tumor necrosis factor therapy. |
BMI, CD, TNF |
| 27 |
2017 |
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naive to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. |
CD, TNF-alpha |
| 28 |
2016 |
Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease. |
CD, CRP, FC, hs |
| 29 |
2016 |
Alterations in glutathione peroxidase and superoxide dismutase activities in plasma and saliva in relation to disease activity in patients with Crohn's disease. |
CD, GPx, ROS, SOD |
| 30 |
2016 |
Clinical efficacy of adalimumab in Crohn's disease: a real practice observational study in Japan. |
ADA, CD |
| 31 |
2016 |
Influence of nutritional status on the therapeutic effect of infliximab in patients with Crohn's disease. |
BMI, CD, IFX, NRI |
| 32 |
2016 |
Investigation of a High-Dose pH-Dependent-Release Mesalazine on the Induction of Remission in Active Crohn's Disease. |
ADRs, AEs, CD, CS |
| 33 |
2016 |
Is ischemia modified albumin a disease activity marker for inflammatory bowel diseases? |
CD, EAI, IBD, IMA, UC |
| 34 |
2016 |
Misdiagnosis and Mistherapy of Crohn's Disease as Intestinal Tuberculosis: Case Report and Literature Review. |
CD, ITB |
| 35 |
2016 |
Mucosal MicroRNAs Expression Profiles before and after Exclusive Enteral Nutrition Therapy in Adult Patients with Crohn's Disease. |
CD, CRP, EEN, miRNAs |
| 36 |
2016 |
Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn's Disease. |
ADR, CD, TB, TNF-alpha |
| 37 |
2015 |
A phase II study of laquinimod in Crohn's disease. |
AEs, CD, TF |
| 38 |
2015 |
An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's disease. |
CD, GMA |
| 39 |
2015 |
Body Mass Index Is a Marker of Nutrition Preparation Sufficiency Before Surgery for Crohn's Disease From the Perspective of Intra-Abdominal Septic Complications: A Retrospective Cohort Study. |
BMI, CD, CI, IASCs, OR |
| 40 |
2015 |
Effect of tumor necrosis factor-alpha antagonists on oxidative stress in patients with Crohn's disease. |
BAP, CD, d-ROM, m-OA, TNF |
| 41 |
2015 |
Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis. |
CD, CENTRAL, UC |
| 42 |
2015 |
Impact of enteral nutrition on energy metabolism in patients with Crohn's disease. |
CD, CRP, EN, ESR, REE, SMM |
| 43 |
2015 |
Prevalence of anemia and iron deficiency in Romanian patients with inflammatory bowel disease: a prospective multicenter study. |
CD, UC |
| 44 |
2015 |
Resources Utilization and Costs the Year Before and After Starting Treatment with Adalimumab in Crohn's Disease Patients. |
CD, DC, IC |
| 45 |
2015 |
Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study. |
CD |
| 46 |
2015 |
Usefulness of C-reactive protein as a disease activity marker in Crohn's disease according to the location of disease. |
CD, CRP |
| 47 |
2014 |
A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. |
CD, CDEIS, MSCs |
| 48 |
2014 |
Bamboo joint-like appearance of the stomach: a stable endoscopic landmark for Crohn's disease regardless of anti-tumor necrosis factor alpha treatment. |
BJA, CD, SES-CD, TNF |
| 49 |
2014 |
Biochemical markers and MR imaging findings as predictors of crohn disease activity in patients scanned by contrast-enhanced MR enterography. |
CD, CDEIS, CI, MR, OR |
| 50 |
2014 |
Contrast-enhanced ultrasonography for the determination of Crohn's disease activity - preliminary experience. |
CD, CEUS, LDCTE, PE, RT, WiR |
| 51 |
2014 |
Doppler ultrasound findings correlate with tissue vascularity and inflammation in surgical pathology specimens from patients with small intestinal Crohn's disease. |
CD, US |
| 52 |
2014 |
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. |
CD, TNF |
| 53 |
2014 |
FDG PET/CT in Crohn's disease: correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity. |
CD, CDEIS, FDG, GCDAS, MAV, PET |
| 54 |
2014 |
Intestinal wall thickness detected by multidetector spiral computed tomography enterography predicts the disease severity of Crohn's disease. |
CD, CRP, MSCTE, SES-CD |
| 55 |
2014 |
Randomized controlled trial: moxibustion and acupuncture for the treatment of Crohn's disease. |
CD, CRP, Hgb |
| 56 |
2013 |
Computed tomography enterography versus balloon-assisted enteroscopy for evaluation of small bowel lesions in Crohn's disease. |
CD, CTE |
| 57 |
2013 |
Correlation between extraintestinal manifestations and clinical parameters with the histologic activity index in patients with inflammatory bowel diseases. |
CD, UC |
| 58 |
2013 |
The impact of early endoscopic lesions on the clinical course of patients following ileocolonic resection for Crohn's disease: A 5-year prospective cohort study. |
CD |
| 59 |
2012 |
Adalimumab therapy following granulocyte and monocyte adsorptive apheresis in a patient with Crohn's disease accompanied by chronic myeloid leukemia. |
CD, CML, GMA |
| 60 |
2012 |
Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn's Disease. |
ADA, anti-TNFalpha, CD, CRP, GMA, SES-CD |
| 61 |
2012 |
Conjugated linoleic acid modulates immune responses in patients with mild to moderately active Crohn's disease. |
CD, CLA, IBDQ |
| 62 |
2012 |
Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation. |
CARD15, CD, IBD5, NOD2 |
| 63 |
2012 |
Current status of mesenchymal stem cell therapy and bone marrow transplantation in IBD. |
CD, HSCT, MSCs |
| 64 |
2012 |
Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): methodology and initial results. |
CCFA, CD, IBD, IQR, MMAS, PROs, SCCAI, SD, SIBDQ, UC |
| 65 |
2012 |
Factors associated with the loss of response to infliximab in patients with Crohn's disease. |
ANA, CD, CIC, GMA, IFX, LOR, sIL-2R |
| 66 |
2012 |
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity. |
CD, CICDA, MPI, ROC, US |
| 67 |
2012 |
Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. |
AE, CD, CRP, IFX, IOIBD |
| 68 |
2012 |
The efficacy of intensive granulocyte and monocyte adsorption apheresis in a patient with Crohn's disease complicated by extensive subcutaneous aseptic neutrophilic abscesses. |
CD, CRP, GMA |
| 69 |
2011 |
A single dose of intravenous zoledronate prevents glucocorticoid therapy-associated bone loss in acute flare of Crohn's disease, a randomized controlled trial. |
BMD, CD, DXA, ZOL |
| 70 |
2011 |
Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial. |
ACCESS, anti-TNF, CD, HBI, s.c |
| 71 |
2011 |
Immunoregulatory effects of adsorptive granulocyte and monocyte apheresis in patients with drug refractory Crohn's disease. |
CD, GMA, TGF |
| 72 |
2011 |
Increases in body mass index during infliximab therapy in patients with Crohn's disease: an open label prospective study. |
BMI, CD |
| 73 |
2011 |
Infliximab therapy impacts the peripheral immune system of immunomodulator and corticosteroid naive patients with Crohn's disease. |
CD, IFN, IFX, IL, TNF |
| 74 |
2011 |
Peripheral Blood CD64 Levels Decrease in Crohn's Disease following Granulocyte and Monocyte Adsorptive Apheresis. |
CD, GMA |
| 75 |
2011 |
[Comparison between staged surgery and one-stage surgery in active complex Crohn disease]. |
CD, CRP, ESR |
| 76 |
2010 |
Association between tumor necrosis factor-alpha and Fc-gamma receptor polymorphisms with infliximab in Crohn's disease. |
CD, FcgammaR, IFX, TNF-alpha |
| 77 |
2010 |
Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study. |
CD, IBDQ, WPAI |
| 78 |
2010 |
Clinical trial: the safety and short-term efficacy of recombinant cholera toxin B subunit in the treatment of active Crohn's disease. |
CD |
| 79 |
2010 |
Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF. |
ATI, CD, CRP, f-IFX, FP-EIA, GII, IFX, TNF |
| 80 |
2010 |
Prospective clinical trial: enteral nutrition during maintenance infliximab in Crohn's disease. |
CD, EN |
| 81 |
2010 |
Selective depletion of peripheral granulocyte/monocyte enhances the efficacy of scheduled maintenance infliximab in Crohn's disease. |
5-ASA, CD, GMA, IFX |
| 82 |
2010 |
[Enteral nutritional therapy in Crohn disease complicated with incomplete intestinal obstruction]. |
CD, EN, PEG/J, TEN |
| 83 |
2009 |
Contrast-enhanced ultrasonographic evaluation of inflammatory activity in Crohn's disease. |
CD, CDUS, CEUS, US |
| 84 |
2009 |
Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study. |
CD, IL |
| 85 |
2009 |
Sargramostim in patients with Crohn's disease: results of a phase 1-2 study. |
CD, s.c |
| 86 |
2009 |
[Maintenance effect of polyglycosides of Tripterygium wilfordii on remission in postoperative Crohn disease]. |
CD |
| 87 |
2008 |
Does clinical response correlate with mucosal healing in patients with Crohn's disease of the small bowel? A prospective, case-series study using wireless capsule endoscopy. |
CD, CI, WCE |
| 88 |
2008 |
Intestinal permeability and its association with the patient and disease characteristics in Crohn's disease. |
CD, IP, LMR |
| 89 |
2008 |
Prevalence and clinical significance of sonographic evidence of mesenteric fat alterations in Crohn's disease. |
CD, OR |
| 90 |
2008 |
Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease. |
CD, EQ-VAS, IBDQ, MCS, PCS, SRMs, WPAI |
| 91 |
2007 |
Chios mastic treatment of patients with active Crohn's disease. |
CD, CRP, IL-6, MCP-1, NRI, TAP, TNF-alpha |
| 92 |
2007 |
Efficacy of T2 in active Crohn's disease: a prospective study report. |
CD, CRP, IL, TNF, TwHF |
| 93 |
2007 |
Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection. |
CD, PP |
| 94 |
2006 |
A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. |
CD |
| 95 |
2006 |
Clinically active Crohn's disease in the presence of a low C-reactive protein. |
CD, CRP |
| 96 |
2006 |
Correlated expression of high-sensitivity C-reactive protein in relation to disease activity in inflammatory bowel disease: lack of differences between Crohn's disease and ulcerative colitis. |
CD, CRP, hs-CRP, IBD, UC |
| 97 |
2006 |
Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. |
CD, DAI, GMA, UC |
| 98 |
2005 |
Anti-Saccharomyces cerevisiae antibody titers are stable over time in Crohn's patients and are not inducible in murine models of colitis. |
CRP, UC |
| 99 |
2005 |
Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. |
CD |
| 100 |
2005 |
Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. |
CD |
|
A Search Service for Abbreviation / Long Form
